Biogen 放弃 Aduhelm 阿尔茨海默氏症药物，将资源转向 Leqembi。 Biogen abandons Aduhelm Alzheimer's drug, redirects resources to Leqembi.

制药公司百健 (Biogen) 决定放弃其阿尔茨海默病药物 Aduhelm。 Biogen, a pharmaceutical company, has decided to abandon its Alzheimer's drug Aduhelm. 该药物备受争议，尽管没有足够的证据证明其益处，但仍于 2021 年获得美国食品和药物管理局 (FDA) 的加速批准。 The drug was highly controversial and was granted accelerated approval by the US Food and Drug Administration (FDA) in 2021, despite insufficient evidence of its benefits. 百健（Biogen）现在将其资源转向 Leqembi，这是该公司与日本制药公司卫材（Eisai）合作开发的另一种阿尔茨海默病药物。 Biogen will now redirect its resources towards Leqembi, another Alzheimer's drug it is developing with Japanese pharmaceutical company Eisai.